Irritable bowel symptoms and the development of common mental disorders and functional somatic syndromes identified in secondary care:a long-term, population-based study by Poulsen, Chalotte Heinsvig et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Irritable bowel symptoms and the development of common mental disorders and
functional somatic syndromes identified in secondary care
Poulsen, Chalotte Heinsvig; Eplov, Lene Falgaard; Hjorthøj, Carsten; Eliasen, Marie;
Skovbjerg, Sine; Dantoft, Thomas Meinertz; Schröder, Andreas; Jørgensen, Torben
Published in:
Clinical Epidemiology
DOI:
10.2147/CLEP.S141344
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Poulsen, C. H., Eplov, L. F., Hjorthøj, C., Eliasen, M., Skovbjerg, S., Dantoft, T. M., ... Jørgensen, T. (2017).
Irritable bowel symptoms and the development of common mental disorders and functional somatic syndromes
identified in secondary care: a long-term, population-based study. Clinical Epidemiology, 9, 393-402.
https://doi.org/10.2147/CLEP.S141344
Download date: 03. Feb. 2020
© 2017 Poulsen et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Clinical Epidemiology 2017:9 393–402
Clinical Epidemiology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
393
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CLEP.S141344
Irritable bowel symptoms and the development  
of common mental disorders and functional 
somatic syndromes identified in secondary  
care – a long-term, population-based study
Chalotte Heinsvig 
Poulsen1,2 
Lene Falgaard Eplov2 
Carsten Hjorthøj2 
Marie Eliasen1 
Sine Skovbjerg1 
Thomas Meinertz Dantoft1 
Andreas Schröder3 
Torben Jørgensen1,4,5
1Research Centre for Prevention and 
Health, Capital Region of Denmark, 
Glostrup, 2Copenhagen University 
Hospital, Mental Health Centre 
Copenhagen, Hellerup, 3Research 
Clinic for Functional Disorders and 
Psychosomatics, Aarhus University 
Hospital, Aarhus, 4Department of 
Public Health, Faculty of Health 
and Medical Sciences, University 
of Copenhagen, Copenhagen, 
5The Faculty of Medicine, Aalborg 
University, Aalborg, Denmark
Objective: Irritable bowel syndrome (IBS) is associated with mental vulnerability, and half of 
patients report comorbid somatic and mental symptoms. We aimed to investigate the relation-
ship between an IBS symptom continuum and the subsequent development of common mental 
disorders (CMDs) and functional somatic syndromes (FSSs).
Methods and study design: A longitudinal population-based study comprising two 5-year 
follow-up studies, Dan-MONICA 1 (1982–1987) and Inter99 (1999–2004), recruited from 
the western part of Copenhagen County. The total study population (n = 7,278) was divided 
into symptom groups according to the degree of IBS definition fulfillment at baseline and/or 
follow-up and was followed until December 2013 in Danish central registries. Cox regression 
was used for the analyses, adjusting for age, sex, length of education and cohort membership. 
In a subsequent analysis, we adjusted for mental vulnerability as a risk factor for both CMDs 
and FSSs, including IBS.
Results: Over a 5-year period, 51% patients had no IBS symptoms, 17% patients had IBS 
symptoms without abdominal pain, 22% patients had IBS symptoms including abdominal pain 
and 10% patients fulfilled the IBS definition. IBS and IBS symptoms including abdominal 
pain were significantly associated with the development of CMDs and other FSSs identified 
in secondary care. When adjusting for mental vulnerability, IBS and IBS symptoms includ-
ing abdominal pain were no longer associated with CMDs, but the significant relationship to 
other FSSs remained.
Conclusion: In a clinical setting, the perspective should be broadened to individuals not ful-
filling the symptom cluster of IBS but who report frequent abdominal pain. Additionally, it is 
important to combine symptom-based criteria of IBS with psychosocial markers such as mental 
vulnerability, because it could guide clinicians in decisions regarding prognosis and treatment.
Keywords: functional gastrointestinal symptoms, abdominal pain, comorbidity, somatization, 
neuroticism
Introduction
With a prevalence of ~11–16%,1,2 “irritable bowel syndrome” (IBS) is a common 
functional gastrointestinal disorder that is associated with substantial costs for patients, 
health care systems and society.3 Approximately half of IBS patients report additional 
mental and somatic symptoms.4 In a Norwegian population-based study, the pres-
ence of comorbid symptoms beyond IBS symptoms was associated with a higher 
functional impairment, more psychological distress and increased health care use.5 
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Thus, IBS patients have an increased prevalence of mental 
disorders, especially anxiety and depression.6 Moreover, 
IBS has a significant symptom overlap with other functional 
gastrointestinal disorders such as dyspepsia and functional 
somatic syndromes (FSSs), eg, fibromyalgia and chronic 
fatigue syndrome.4,7 These findings illustrate the need for 
more knowledge about the prognosis of IBS, eg, the poten-
tial development of mental and functional comorbidities. 
This knowledge could guide clinicians and policy makers 
in decisions regarding treatment, disease prevention and 
health-promoting strategies.
Most of the literature in this field has certain method-
ological limitations such as cross-sectional design, selected 
patient populations and uncertainties in delimitation of the 
FSSs including IBS.4,6,7 Recently, IBS has been defined as a 
disorder of gut–brain interaction;8 that is why studies focusing 
on IBS and subsequent development of mental and functional 
comorbidities have become of increasing interest.9–12 Never-
theless, the focus is on IBS and “non-IBS” cases, although 
other population-based studies have shown the importance 
of broadening the perspective to individuals not fulfilling the 
symptom cluster of IBS.2,13,14 Additionally, other population-
based studies have shown that mental vulnerability, illness 
anxiety and somatic symptom burden predict development of 
IBS.15,16 These results indicate the need for addressing both 
somatic and psychological factors in the early examination 
of individuals with IBS. Mental vulnerability represents both 
a symptom state related to somatization and a personality 
trait related to neuroticism.17 Neuroticism has been shown 
to be a risk marker in the development of common mental 
disorders (CMDs).18 In addition, both neuroticism and soma-
tization have been linked to the development of IBS and other 
FSSs.19,20 Therefore, long-term population-based studies 
taking psychosocial factors such as mental vulnerability into 
account are warranted. In the present study, we hypothesized 
that mental and functional comorbidities also are present 
among individuals not fulfilling the IBS definition. We 
therefore broadened the perspective to a continuum of IBS 
symptoms in a general population. Furthermore, we com-
bined cohort studies with Danish nationwide registers and 
aimed to investigate the association between IBS symptoms 
and the subsequent development of CMDs and FSSs other 
than IBS. Additionally, we hypothesized that mental vulner-
ability can act as a confounder, because it may contribute 
to both predisposition and maintenance of IBS symptoms.19 
We therefore aimed to investigate these associations both 
with and without taking mental vulnerability into account.
Methods and study design
The study design has previously been presented as a longi-
tudinal study consisting of two population-based cohorts, 
Dan-MONICA 1 (1982–1987) and Inter99 (1999–2004), 
both examined twice with 5-year interval.14 The two cohorts 
were followed until December 2013 in Danish central 
registries.
Study populations
The two study populations have previously been described in 
detail.21,22 They were drawn as age- and sex-matched samples 
from the Danish Civil Registration System (CRS) using 
computer-generated random numbers. Both study popula-
tions were recruited from the western part of Copenhagen 
County, which constitutes 7% of the total Danish population 
and is representative of Danes living in the suburbs. In brief, 
the Dan-MONICA 1 study population comprised 4,807 men 
and women of ages 30, 40, 50 and 60 years.21 All individuals 
were invited for a general health examination conducted in 
1982–1984. Individuals not of Danish nationality (n = 226) 
were excluded, reducing the sample to 4,581. Of them, 3,608 
(79%) individuals participated in the baseline study. At the 
5-year follow-up, 3,498 individuals were accessible for invi-
tation to a similar health examination. Among them, 2,987 
(85%) individuals participated. Individuals not responding 
were re-invited twice.23 The Inter99 study population com-
prised 13,016 men and women of ages 30, 35, 40, 45, 50, 55 
and 60 years.22 Eligible individuals (n = 12,934) were invited 
for a health screening program conducted in 1999–2001, 
and 6,906 (53%) individuals turned up for the examination. 
Individuals with linguistic barriers, alcoholism or drug 
abuse were excluded, leaving 6,784 (52.5%) participants 
in the baseline study. The Inter99 study was designed as an 
intervention study for prevention of ischemic heart disease. 
The participants were therefore divided into two random 
samples: a high-intensity intervention group (A) and a low-
intensity intervention group (B). At the 5-year follow-up, 
6,536 individuals were accessible for invitation to the second 
study. Among them, 4,513 (69%) individuals participated. 
Individuals not responding were re-invited.24 Both cohorts 
comprised information on self-reported IBS symptoms 
from a questionnaire and were pooled in the present study, 
reducing the sample to 7,500 individuals who participated 
both at baseline and at 5-year follow-up. The data from 
Dan-MONICA 1 and Inter99 are available for researchers 
who meet the criteria, for access to confidential data contact 
information: torben.joergensen@regionh.dk.
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IBS symptom groups
The used IBS definition was based on a symptom cluster of 
frequent self-reported IBS symptoms in the past 12 months 
found in a previous study of Dan-MONICA 1: “Individuals 
stating that they often experience both abdominal pain and 
distension and, additionally, either borborygmus or altering 
stool consistency, or both”.25 Frequent IBS symptoms were 
defined as experiencing them at least once a month (abdomi-
nal pain) or frequently or daily/almost constantly (distension, 
borborymus and altering stool consistency). The total study 
population was divided into four symptom groups according 
to the degree of IBS definition fulfillment at baseline and/
or 5 years follow-up: 1) IBS; 2) IBS symptoms including 
abdominal pain; 3) IBS symptoms without abdominal pain 
and 4) reference group without IBS symptoms. Individuals in 
group 1 fulfilled the IBS definition at baseline and/or 5-year 
follow-up. Individuals in group 2 and 3 had IBS symptoms 
with and without abdominal pain at baseline and/or at 5-year 
follow-up but did not fulfill the IBS definition at any time. 
The reference group had no IBS symptoms at baseline or at 
5-year follow-up. The symptom groups have previously been 
presented. The study showed that fulfillment of the used IBS 
definition delimitated individuals not associated with severe 
gastrointestinal diseases including inflammatory bowel disor-
ders.14 In total, 222 individuals were excluded from the study 
population due to missing data on IBS symptoms, reducing 
the sample to 7,278 individuals.
Outcomes
The total study population was linked through the unique 
personal identification number to the CRS, the Danish Psy-
chiatric Central Research Register (PCRR) and the National 
Patient Register (NPR). The personal identification number is 
used in all the registries, insuring complete linkage between 
databases. The information in the CRS is considered to be of 
high validity.26 Although both the content and the definitions 
of single variables may have changed over time, the PCRR 
and the NPR are considered as valuable tools in epidemio-
logical research.27,28 In this study, we obtained information on 
psychiatric and somatic inpatient admissions from the PCRR 
since 1969 and the NPR since 1977 until the end of register 
extraction (December 31, 2013). From 1995 and onward, the 
registers also included information of outpatient treatment 
and emergency room contacts. We based the delimitation 
of CMDs and other FSSs on systematic reviews and recent 
register-based studies on the most common mental and 
functional comorbidities in IBS.4,6,7,10,29 Thus, CMDs were 
defined as first hospital contact with a diagnosis of a neurotic, 
stress-related, anxiety or mood affective disorder classified 
according to the International Classification of Diseases revi-
sion 8 (ICD-8) and International Classification of Diseases 
revision 10 (ICD-10; Table 1). Hypochondriasis was included 
as an anxiety disorder, because both scientific evidence and 
clinical evidence support the view that it is a distinct “health 
anxiety” disorder that can be treated effectively and only 
partly overlaps with FSSs.30 Other FSSs were defined as 
first hospital contact for a diagnosis of interstitial cystitis, 
postviral fatigue syndrome, malaise and fatigue, myalgia/
rheumatism unspecified, fibromyalgia, pain not elsewhere 
classified, temporomandibular joint disorders, sprain and 
strain of cervical spine (whiplash), somatoform disorders 
and neurasthenia classified according to ICD-8 and ICD-10 
(Table 1).4,6,7,10 In the delimitation, we included unspecific 
symptom codes due to uncertainties in the registration prac-
tice of the syndrome codes.10 We did not include functional 
gastrointestinal disorders due to the significant symptom 
overlap with IBS.31,32
Covariates
Age at health examination and sex were obtained from the 
CRS. Education was self-reported and obtained from the 
questionnaires used at the health examinations.21,22 Length of 
education was categorized as no/under education, <2 years of 
education (short education, special workers or apprentices), 
2–4 years of education (middle length education or techni-
cian training) and >4 years of education (academic or higher 
education). Only eight individuals were under education, and 
they were categorized as individuals not having an education. 
The Mental Vulnerability Questionnaire was developed by 
the Military Psychological Services in Denmark in the 1960s 
and used as a screening instrument to assess mental fitness 
for military service. The questionnaire was similar to inter-
national instruments developed in the same period.33,34 We 
used the 12-item Mental Vulnerability Scale (Table S1) that 
was developed from a 22-item scale derived from the original 
27-item Mental Vulnerability Questionnaire.35 The 12-item 
Mental Vulnerability Scale has been shown to be a predictor 
of several health outcomes, including IBS, upper dyspepsia 
and depression.15,36–38 Moreover, the 12-item scale has been 
validated as a reliable and stable measure of overall mental 
vulnerability.17 Mental vulnerability was categorized as not 
vulnerable (zero to two affirmative answers), moderately 
vulnerable (three to four affirmative answers) and highly 
vulnerable (five or more affirmative answers).
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Statistical analysis
We analyzed data using SAS 9.3 software (SAS Institute Inc., 
Cary, NC, USA). The associations between each of the symp-
tom groups, CMDs and FSSs were assessed using Cox pro-
portional hazards regression models to estimate hazard ratios 
(HRs) with 95% confidence intervals (CIs). Follow-up time 
was calculated as the time from the 5-year follow-up assess-
ment to event or censoring, because the exposed individuals 
were defined according to IBS symptoms at both baseline 
and 5-year follow-up. Individuals who had a diagnosis of a 
CMD (n = 249) or an FSS (n = 216) before the follow-up 
assessment were excluded. Furthermore, a total of 282 and 
285 individuals were censored due to migration before the 
follow-up study, leaving 6,747 and 6,777 individuals for the 
primary analyses of CMDs and FSSs, respectively. Individu-
als were followed until first contact to the secondary health 
care system with a CMD or an FSS diagnosis and censored 
at first migration, death or December 31, 2013, whichever 
came first. Analyses were adjusted for cohort membership, 
which was created as a three-level variable consisting of 
Dan-MONICA 1 and Inter99 intervention group (A) and 
(B). Additionally, analyses were adjusted for age, sex and 
length of education. Mental vulnerability can be viewed as 
a confounder on the outcomes. In a subsequent analysis, we 
therefore adjusted the results for mental vulnerability and 
presented the results both with and without this additional 
adjustment. Furthermore, we conducted a sensitivity analysis 
where the item “Do you often have pain in different parts 
of your body, eg, your stomach, neck, back or chest?” was 
excluded from the 12-item mental vulnerability scale due to 
the possible symptom overlap with the abdominal pain item 
in the IBS definition. Moreover, we performed an additional 
Cox regression to investigate the associations between men-
tal vulnerability and the outcomes. The associations were 
investigated both with and without taking IBS at baseline 
into account.
Table 1 Definitions of CMDs and FSSs according to ICD-8 and  ICD-10
Classification Codes Classification Codes
ICD-8 (1965) ICD-10 (1990)
Neurotic, stress-related and anxiety disorders
Phobic neurosis 300.29 Phobic anxiety disorders F40
Anxiety/hysterical neurosis 300.09–300.19 Other anxiety disorders F41
Obsessive–compulsive neurosis 300.39 Obsessive–compulsive disorder F42
– – Reaction to severe stress and adjustment 
disorders
F43
Depersonalization syndrome 300.69 Dissociative (conversion) disorders F44
Hypochondriacal neurosis and other 300.79–300.99 Hypochondriacal disorder F45.2
Mood affective disorders
Manic-depression psychosis, manic/circular 
type
296.19+296.39 Manic episode and bipolar disorders F30–F31
Affective psychoses, depressed type 296.09+296.29+
296.89+296.99+
300.49
Depressive episode and recurrent depressive 
disorders
F32–F33
– – Other mood affective disorders F34–F39
Functional somatic syndromes
– – Interstitial cystitis (chronic) N30.1
– – Postviral fatigue syndrome G93.3
– – Malaise and fatigue R53
Other muscular rheumatism, fibrositis and 
myalgia
717.99 Myalgia/rheumatism unspecified M79.0–M79.1
– – Fibromyalgia M79.7
– – Pain – not elsewhere classified R52
– – Temporomandibular joint disorders K.07.6
Sprain and strain of other and unspecified 
parts of back
N847 Sprain and strain of cervical spine (whiplash) S13.4
Physical disorders, presumably of 
psychogenic origin
305 Somatoform disorders F45–F45.1+F45.3–F45.9
Neurasthenia 300.59 Neurasthenia F48.0
Abbreviations: CMDs, common mental disorders; FSSs, functional somatic syndromes; ICD-8, International Classification of Diseases revision 8; ICD-10, International 
Classification of Diseases revision 10.
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Ethical approval
Dan-MONICA 1 and Inter99 were approved by the local 
ethical committee at the time of data collection.21,22 The 
participants were informed that all information was to be 
used for research purposes only and gave written informed 
consent. The present study was approved by the Danish Data 
Protection Agency (2012-58-0009).
Results
The IBS symptom groups and the baseline characteristics 
are presented in Table 2. Further details can be found else-
where.14 In the pooled cohort, 714 (10%) patients had IBS, 
1,589 (22%) patients had IBS symptoms including abdomi-
nal pain, 1,276 (17%) patients had IBS symptoms without 
abdominal pain and 3,699 (51%) patients reported no IBS 
symptoms over the 5-year period. At baseline, mental vulner-
ability significantly increased with increasing fulfillment of 
the IBS definition. In total, 56% of patients with IBS were 
moderately/highly vulnerable, whereas 10% of those without 
IBS symptoms were moderately/highly vulnerable (Table 2).
Development of CMDs and FSSs 
identified in secondary care
There was an increased risk of CMD development in second-
ary care both among individuals with IBS and IBS symptoms 
including abdominal pain (HR: 1.74 [95% CI: 1.18–2.56] 
and HR: 1.74 [95% CI: 1.31–2.31], respectively; Table 3) 
compared to individuals reporting no IBS symptoms. IBS 
symptoms without abdominal pain were not associated with 
subsequent registration of CMDs identified in secondary care 
(HR: 1.23 [95% CI: 0.87–1.73]; Table 3). When addition-
ally adjusting the results for mental vulnerability, the HR 
estimates decreased, and overall, the IBS symptom groups 
were not significantly associated with CMD development in 
secondary care (Table 3). The sensitivity analysis using the 
reduced mental vulnerability scale showed an increased risk 
of CMD development among individuals with IBS symptoms 
including abdominal pain, but the overall association between 
symptom groups and the outcome remained insignificant. 
Across all symptom groups, depression, other anxiety, 
reaction to severe stress and adjustment disorders were the 
most frequent CMDs registered in secondary care (data not 
shown). There was an increased risk of FSS development in 
secondary care both among individuals with IBS and IBS 
symptoms including abdominal pain (HR: 1.94 [95% CI: 
1.34–2.80] and HR: 1.76 [95% CI: 1.31–2.35], respectively; 
Table 4) compared to individuals reporting no IBS symptoms. 
IBS symptoms without abdominal pain were not associated 
with subsequent registration of FSSs identified in second-
ary care (HR: 1.32 [95% CI: 0.94–1.85]; Table 4). When 
additionally adjusting the results for mental vulnerability, the 
HR estimates decreased, but the overall association between 
symptom groups and the development of FSSs remained sta-
tistically significant (Table 4). The sensitivity analysis using 
Table 2 Irritable bowel symptom groups and baseline characteristics, pooled Dan-MONICA 1 and Inter99 cohort, n = 7,278
Baseline characteristics IBS, n (%) IBS symptoms including 
abdominal pain, n (%)
IBS symptoms without 
abdominal pain, n (%)
Reference: no IBS 
symptoms, n (%)
p
Pooled cohort 714 (10) 1,589 (22) 1,276 (17) 3,699 (51)
Dan-MONICA 1 cohort (n = 2,955) 249 (8) 724 (25) 469 (16) 1,513 (51) <0.001*
Inter99 cohort (n = 4,323) 465 (11) 865 (20) 807 (19) 2,186 (50)
Age (years)
Mean age (standard deviation) 43.8 (8.6) 44.5 (9.3) 45.5 (9.0) 46.6 (9.3) <0.001**
Sex
Women 510 (71) 910 (57) 677 (53) 1,517 (41) <0.001***
Men 204 (29) 679 (43) 599 (47) 2,182 (59)
Length of educationa
No/under educationb 109 (16) 246 (16) 182 (15) 458 (13) <0.001***
<2 years of education 203 (30) 554 (36) 368 (30) 1,161 (33)
2–4 years of education 312 (46) 632 (41) 566 (46) 1,565 (44)
>4 years of education 50 (8) 104 (7) 104 (9) 362 (10)
Mental vulnerabilityc
Highly vulnerable 188 (26) 211 (13) 96 (7) 88 (2) <0.001***
Moderately vulnerable 209 (30) 325 (21) 225 (18) 290 (8)
Not vulnerable 315 (44) 1,051 (66) 955 (75) 3,318 (90)
Notes: aMissing items on length of education (n = 302). bIndividuals under education (n = 8) were categorized as individuals not having an education. cMissing items on mental 
vulnerability (n = 7). *Multinomial logistic regression adjusted for age and sex. **Kruskal–Wallis test. ***Chi-square test.
Abbreviation: IBS, irritable bowel syndrome.
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the reduced mental vulnerability scale slightly increased 
the HR estimates, and the association remained significant 
(Table 4). In the registration of FSSs in secondary care, the 
syndrome codes were infrequently used compared to the 
unspecified symptom codes. Across all symptom groups, pain 
not elsewhere classified, myalgia/rheumatism unspecified 
and malaise and fatigue were the most frequently registered 
diagnoses (data not shown).
There was no statistically significant interaction between 
the IBS symptom groups and cohort membership on any 
outcome (p > 0.05). A high/moderate mental vulnerability 
was statistically significantly associated with subsequent 
CMDs and FSSs (HR: 2.72 [95% CI: 2.14–3.45] and HR: 
1.97 [95% CI: 1.54–2.52], respectively). When accounting 
for the IBS symptom group at baseline, the estimates slightly 
decreased (HR: 2.53 [95% CI: 1.96–3.26] and HR: 1.72 
[95% CI: 1.32–2.24], respectively), but the overall significant 
association between mental vulnerability and the outcomes 
remained (both p < 0.001).
Discussion
Individuals both fulfilling and not fulfilling the IBS definition 
but who reported IBS symptoms including abdominal pain 
more often developed CMDs and FSSs identified in second-
ary care compared to individuals reporting no IBS symptoms. 
Individuals with IBS symptoms without abdominal pain 
were not associated with subsequent CMDs or FSSs. When 
accounting for mental vulnerability, the estimates decreased 
and only the associations between IBS, IBS symptoms 
including abdominal pain and the development of other FSSs 
remained significant.
Interpretation and explanation of the 
findings
Mental vulnerability is defined as a low threshold for sus-
ceptibility.38 Psychometric evaluation has shown that the 
12-item mental vulnerability scale has a strong association 
with somatization and the personality trait neuroticism.17 
Somatization refers to a tendency to experience and com-
municate somatic distress in response to psychosocial stress 
and seek medical help for it.39 Neuroticism is widely defined 
as a tendency to experience negative emotions and bodily 
sensations, especially when threatened, frustrated or facing 
loss.18 In this study, mental vulnerability showed to be a strong 
predictor of both outcomes, independent of the presence of 
IBS. The primary results indicated that when accounting for 
the tendency to be mentally vulnerable, individuals reporting 
IBS symptoms in a general population were not more likely to 
Table 3 Development of CMDs identified in secondary care for each irritable bowel symptom group, pooled Dan-MONICA 1 and 
Inter99 cohort
Irritable bowel symptom groups CMDs, n HR (95% CI)a,  
n = 6,480b
pf HR (95% CI)c,  
n = 6,477d
pf HR (95% CI)c,  
n = 6,477d
pf
–MV adjustment +MV adjustment +MV adjustmente
IBS 37 1.74 (1.18–2.56) 1.06 (0.70–1.61) 1.18 (0.78–1.77)
IBS symptoms including abdominal pain 90 1.74 (1.31–2.31) 1.31 (0.98–1.76) 1.39 (1.04–1.87)
IBS symptoms without abdominal pain 47 1.23 (0.87–1.73) 1.11 (0.77–1.54) 1.10 (0.78–1.56)
Reference: no IBS symptoms 116 1 <0.001 1 0.32 1 0.17
Notes: aAdjusted for age, sex, length of education and study cohort. bMissing items on length of education (n = 267). cAdjusted for age, sex, length of education, study cohort 
and mental vulnerability. dMissing items on length of education (n = 267) and mental vulnerability (n = 3). eReduced mental vulnerability scale without the item about pain in 
different parts of body, eg, stomach, neck, back and chest. fCox regression: overall statistical association between symptom groups and CMDs.
Abbreviations: CMDs, common mental disorders; HR, hazard ratio; CI, confidence interval; MV, mental vulnerability; IBS, irritable bowel syndrome.
Table 4 Development of other FSSs for each irritable bowel symptom group, pooled Dan-MONICA 1 and Inter99 cohort
FSSs, n HR (95% CI)a,  
n = 6,507b
pf HR (95% CI)c,  
n = 6,504d
pf HR (95% CI)c,  
n = 6,504d
pf
–MV adjustment +MV adjustment +MV adjustmente
IBS 43 1.94 (1.34–2.80) 1.48 (1.00–2.20) 1.63 (1.11–2.40)
IBS symptoms including abdominal pain 83 1.76 (1.31–2.35) 1.52 (1.12–2.06) 1.60 (1.19–2.16)
IBS symptoms without abdominal pain 49 1.32 (0.94–1.85) 1.21 (0.86–1.71) 1.26 (0.90–1.77)
Reference: no IBS symptoms 116 1 <0.001 1 0.043 1 0.010
Notes: aAdjusted for age, sex, length of education and study cohort. bMissing items on length of education (n = 270). cAdjusted for age, sex, length of education, study cohort 
and mental vulnerability. dMissing items on length of education (n = 270) and mental vulnerability (n = 3). eReduced mental vulnerability scale without the item about pain in 
different parts of body, eg, stomach, neck, back and chest. fCox regression: overall statistical association between symptom groups and FSSs.
Abbreviations: FFSs, functional somatic syndromes; HR, hazard ratio; CI, confidence interval; MV, mental vulnerability; IBS, irritable bowel syndrome.
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be classified in secondary health care with CMDs than indi-
viduals without IBS symptoms. In addition, both neuroticism 
and somatization have been linked to explain the frequent 
comorbid symptoms and related functional comorbidities 
of IBS.4,20 Our study indicated that the association between 
IBS symptoms and the subsequent registration of other FSSs 
could not be explained by mental vulnerability only.
Relation to other studies
In this longitudinal study of a general adult Danish popula-
tion, we found that 10% fulfilled the definition of IBS over 
a 5-year follow-up period. Moreover, 56% of these individu-
als reported comorbid symptoms and traits equivalent to a 
moderate or high mental vulnerability. Mental vulnerability 
has been shown to be a predictor of increased health care use 
and a broad variety of health outcomes.37,40,41 In this study, 
we confirmed previous longitudinal findings that IBS is 
associated with subsequent development of CMDs.9,11,12 For 
example, a large register-based study from Taiwan showed 
an increased risk of depression, anxiety, sleep and bipolar 
disorders following a diagnosis of IBS.9 However, the study 
was based on a selected patient population newly diagnosed 
with IBS caused by gastroenteritis. In our population-based 
sample, we showed this increased risk also among individuals 
not fulfilling the symptom cluster of IBS over a 5-year period 
but who reported frequent abdominal pain. A recent nation-
wide Italian cohort study found a significant relationship 
between migraine/headache, IBS and fatigue among primary 
care patients and later development of depressive disorders 
in general practice.42 Our study added that the increased 
risk of CMDs in secondary care is likely to be explained by 
subgroups of individuals with IBS symptoms who also are 
mentally vulnerable.
An 8-year follow-up study of 493 Swedish IBS patients 
identified in primary care showed a similar mental and func-
tional comorbidity pattern in secondary care compared to our 
study.10 However, the two studies were difficult to compare 
due to different methods, differences in delimitation of IBS 
and lack of information about the specific register diagnoses 
used. In our population-based study, we showed an increased 
risk of FSS development also among individuals not fulfill-
ing the IBS definition over a 5-year period but who reported 
frequent abdominal pain. These findings support the growing 
recognition that there is a significant overlap among FSSs 
with persistent pain as a predominant feature. Moreover, 
there has been a growing recognition of a shared underlying 
mechanism, primarily central sensitization of the central 
nervous system.43 In addition, bidirectional communication 
from the gut to the brain and from the brain to the enteric 
nervous system is likely to explain symptoms outside the 
gastrointestinal system.44 Although the precise mechanisms 
are not fully understood, it is possible that these “gut–brain” 
pathways play a role in the development of mental comor-
bidity and functional comorbidity at least in subgroups of 
patients with IBS.
Methodological considerations
Until now, few population-based studies have investigated the 
associations between IBS and subsequent CMDs and FSSs 
identified in secondary care. Furthermore, none of these stud-
ies have included mental vulnerability or performed subgroup 
analyses based on the nature of IBS symptom reporting.9–12 
In this study, the exposure was based on the 5-year follow-up 
period and we focused on the long-term incidence of CMDs 
and FSSs in the two time periods 1987–2014 and 2004–2014. 
The linkage to Danish national registers ensured accurate 
and precise information about deaths, migration and date 
of first hospital contact with a specific diagnostic code. The 
diagnoses in the registers were registered by medical special-
ists in secondary care.
The available data were not collected to define IBS 
according to the present Rome IV criteria.8 The Rome criteria 
developed at the time of data collection were not sufficient to 
define IBS in a general population (abdominal pain was not 
mandatory and the criteria did not require any frequency of 
symptoms).45 Therefore, we used an IBS definition defined 
according to valid statistical criteria in population-based 
data.25,46 However, it was a limitation that we only had infor-
mation on self-reported IBS symptoms in the past 12 months 
and no information on symptom duration and severity. 
This could have introduced some misclassification of IBS. 
Nevertheless, in this study, we focused on self-reported IBS 
symptoms in a general population and not on incident IBS 
patients. With this symptom approach, we did not delimitate 
IBS from other functional gastrointestinal disorders.
The focus on IBS symptoms among individuals par-
ticipating in two general health examinations could have 
introduced some selection bias toward a more healthy 
population sample. Some of the nonparticipants and the 
nonattenders to the 5-year follow-up studies could have been 
individuals with persistent and severe symptoms. Moreover, 
the exclusion of previous diagnoses with CMDs and FSSs 
could have excluded the most vulnerable individuals. This 
could imply an underestimation of the association between 
fulfillment of IBS and the outcomes. The possible selec-
tion bias may be largest in the Inter99 study due to the low 
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participation rate and its intervention design. However, we 
found no  significant interaction between cohort membership 
and the IBS symptom groups in relation to the outcomes, 
indicating that this selection bias was of lower importance. 
Nevertheless, Koloski et al. have shown that gut-brain path-
ways in IBS are bi-directional.12 Therefore, the study design 
limited the focus to individuals with IBS developing mental 
and functional comorbidities later in life. Individuals were 
randomly selected from the CRS and were therefore equally 
likely to be selected to the study. However, only individu-
als of age 30–60 years were invited, and individuals not 
of Danish nationality were excluded, because the study is 
primarily generalizable to an adult Danish-speaking popula-
tion. In relation to the outcomes, we only had information 
about severe CMDs treated in secondary care and we did not 
have information about milder versions of these conditions 
treated in primary care. Moreover, the registration practice 
of FSSs across medical specialties is unclear and may have 
changed over time. We addressed this limitation by including 
unspecific symptom diagnoses in our delimitation of FSSs. 
As expected, the syndrome diagnoses were infrequently used 
compared to the unspecific symptom diagnoses. Finally, 
we included few potential confounders due to uncertainties 
about risk factors to IBS and did not address other possible 
explaining factors such as gastrointestinal infections,16 food 
intolerances47 and use of medicine.48
Conclusion and implications
Mental vulnerability may explain the increased risk of CMD 
development in secondary care among individuals reporting 
IBS symptoms. Moreover, individuals with abdominal pain 
including those fulfilling the IBS definition have an increased 
risk of FSS development in secondary care, and this associa-
tion cannot be explained by mental vulnerability only. These 
findings support the recognition of a significant overlap 
among FSSs. In a clinical setting, it is important to broaden 
the perspective to patients not fulfilling the symptom cluster 
of IBS and especially patients reporting frequent abdominal 
pain. Additionally, it is important to combine symptom-based 
criteria of IBS with psychosocial markers such as mental 
vulnerability, because it could guide clinicians in decisions 
regarding prognosis and treatment.
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Supplementary material
Table S1 The 12-item mental vulnerability scale
We would like to ask you some questions regarding your personal well-being. Please do not think too much about the answers – 
just answer as you find most suitable
1. Do your hands easily shake?
2. Do you often suffer from loss of appetite?
3. Do you often suffer from sleeplessness?
4. Do you often feel very tired?
5. Do you often take medicine, such as headache tablets, sleeping pills, tranquilizers or the like?
6. Do you often have pain in different parts of your body, eg, your stomach, neck, back or chest?
7. Do you often suffer from fits of dizziness?
8. Does your heart often beat very fast for no particular reason?
9. Is it difficult for you to make friends?
10. Do small things get on your nerves?
11. Do you constantly have thoughts which trouble and worry you?
12. Do you usually feel misunderstood by other people?
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